Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

Table 4 Correlation with disease-free survival (Cox regression analysis)

	n	events	3-year survival rate (%)	hazard ratio	95% CI	p
biology-based tumor type	105	27				< 0.0001^a
HR+/HER2-	56	8	96.3	1.00
HR+/HER2+	13	2	90.0	1.26	0.27-5.98	0.770
HR-/HER2+	12	8	33.3	9.32	3.45-25.13	< 0.0001
HR-/HER2-	24	9	65.0	2.23	1.24-8.40	0.016
Ki67	96	21
<= 20%	79	16	87.7	1.00
> 20%	17	5	70.6	1.43	0.52-3.94	0.486
pCR	105	27
no pCR	95	26	80.0	1.00
pCR	10	1	90.0	0.29	0.04-2.15	0.227
ypN	105	27
ypN0	65	13	83.1	1.00
ypN1-2	40	14	52.4	2.46	1.142-5.302	0.021

ISSN: 1465-542X